Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company Drug

Immupeutics Medicine Secures NMPA Approval for Personalized Liver Cancer Immunotherapy IPM001

Fineline Cube Oct 12, 2024

Immupeutics Medicine, a pioneer in tumor immunotherapy based in Beijing, has announced that it has...

Company Deals

Eli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development

Fineline Cube Oct 12, 2024

Eli Lilly & Co. (NYSE: LLY), a stalwart of the US pharmaceutical industry, has inked...

Company Drug

Pfizer’s Hympavzi Secures FDA Nod, Offering Novel Once-Weekly Treatment for Hemophilia B

Fineline Cube Oct 12, 2024

Pfizer Inc. (NYSE: PFE) has scored a significant win with the US Food and Drug...

Company Deals

Hetero and Gilead Sciences Partner to Expand Access to HIV Treatment in Low-Income Countries

Fineline Cube Oct 12, 2024

Indian pharmaceutical company Hetero has announced a new partnership with US healthcare giant Gilead Sciences...

Company Drug

Huadong Medicine Secures NMPA Approval for Semaglutide Biosimilar, Aims to Capture Weight Loss Market

Fineline Cube Oct 11, 2024

Nanjing-based Huadong Medicine Co., Ltd (SHE: 000963) has received clinical trial approval from China’s National...

Company Drug

Coherent Biopharma’s CBP-1008 Earns FDA Fast Track for Platinum-Resistant Ovarian Cancer

Fineline Cube Oct 11, 2024

Coherent Biopharma Ltd, a specialist in bispecific-ligand drug conjugates (Bi-XDCs) with operations in Suzhou, China,...

Company Drug

Doma Biopharmaceutical Receives Green Light for Clinical Trial of Novel ADC DM001 Targeting Solid Tumors

Fineline Cube Oct 11, 2024

Doma Biopharmaceutical (Suzhou) Co., Ltd, a biotech firm with a presence in China and the...

Company Drug

Harbour BioMed’s Innovative Antibody Porustobart Shows Promise in Early Clinical Trials for Melanoma

Fineline Cube Oct 11, 2024

Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands,...

Company Deals

Eli Lilly Expands Collaboration with KeyBioscience to Develop Obesity Treatments Using DACRA Platform

Fineline Cube Oct 11, 2024

Eli Lilly and Company (NYSE: LLY) has announced an extension of its collaboration with KeyBioscience...

Company Deals

XtalPi’s AI Platform XtalFold Secures Licensing Deal with Janssen Biotech, Enhancing Biologics Discovery

Fineline Cube Oct 11, 2024

XtalPi (QuantumPharm, HKG: 2228) a leading AI-driven drug discovery firm based in Shenzhen and known...

Company Drug

Roche’s Genentech Scores FDA Approval for Itovebi in Advanced Breast Cancer Treatment, Advancing Personalized Oncology

Fineline Cube Oct 11, 2024

Roche (SWX: ROG)’s Genentech, a leader in pharmaceutical innovation, has received approval from the US...

Company Drug

Johnson & Johnson’s Darzalex Combo Therapy Gets EMA Nod for Multiple Myeloma, Aims to Set New Standard

Fineline Cube Oct 11, 2024

Johnson & Johnson (NYSE: JNJ) has taken a significant step in expanding its oncology portfolio...

Company Drug

Jiangsu Hengrui’s SHR2554 Gets Priority Review for Lymphoma Treatment, Strengthening Global EZH2 Inhibitor Market

Fineline Cube Oct 11, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) is on the brink of a breakthrough in...

Company Drug

Jiangsu Hengrui Secures FDA Nod for Generic Abraxane, Strengthening Oncology Portfolio

Fineline Cube Oct 11, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has achieved a first in the US market...

Company Medical Device

Roche’s VENTANA CLDN18 Assay Receives EU Approval, Enhances Targeted Therapy Options for Gastric Cancer

Fineline Cube Oct 11, 2024

Roche (SWX: ROG; OTCMKTS: RHHBY) has secured CE Mark approval in the European Union for...

Company Drug

Biogen Gains FDA Breakthrough Status for Felzartamab in Kidney Transplant Rejection Treatment

Fineline Cube Oct 11, 2024

Biogen Inc. (NASDAQ: BIIB) has secured breakthrough therapy designation (BTD) from the U.S. Food and...

Company

Eli Lilly & Co. Boosts Suzhou Plant with $211M to Meet Diabetes and Obesity Drug Demand

Fineline Cube Oct 11, 2024

Eli Lilly & Co.(NYSE: LLY)’s China subsidiary is poised to invest a substantial RMB 1.5...

Legal / IP Policy / Regulatory

China’s NMPA Proposes Rewards for Internal Whistleblowers in Drug and Medical Device Safety Reporting

Fineline Cube Oct 11, 2024

The National Medical Products Administration (NMPA) of China has issued a draft proposal for the...

Company Drug Medical Device

Sunvozertinib’s Companion Diagnostic Gets NMPA Nod, Fortifying Targeted Therapy Arsenal for NSCLC in China

Fineline Cube Oct 11, 2024

Dizal Pharmaceutical Co., Ltd (SHA: 688192) and Burning Rock Ltd (NASDAQ: BNR, FRA: 6BU0) have...

Company Medical Device

Sino Medical Sciences Secures NMPA Nod for Balloon Guided Catheter to Aid Vascular Procedures

Fineline Cube Oct 10, 2024

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced that it has received marketing...

Posts pagination

1 … 338 339 340 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.